Biogen (BIIB) Expected to Announce Earnings on Thursday

Biogen (NASDAQ:BIIB - Get Free Report) is projected to post its Q1 2025 quarterly earnings results before the market opens on Thursday, May 1st. Analysts expect Biogen to post earnings of $3.59 per share and revenue of $2.25 billion for the quarter. Biogen has set its FY 2025 guidance at 15.250-16.250 EPS.

Biogen (NASDAQ:BIIB - Get Free Report) last released its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.87%. On average, analysts expect Biogen to post $16 EPS for the current fiscal year and $17 EPS for the next fiscal year.

Biogen Stock Up 0.9 %

BIIB stock traded up $1.05 during midday trading on Tuesday, hitting $120.17. The company's stock had a trading volume of 1,003,166 shares, compared to its average volume of 1,346,011. The company has a market cap of $17.59 billion, a PE ratio of 10.74, a P/E/G ratio of 1.51 and a beta of 0.06. Biogen has a 12 month low of $110.04 and a 12 month high of $238.00. The company has a current ratio of 1.35, a quick ratio of 0.90 and a debt-to-equity ratio of 0.27. The firm's 50-day moving average is $131.78 and its 200-day moving average is $148.18.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. Argus lowered shares of Biogen from a "buy" rating to a "hold" rating in a research note on Friday, April 4th. Morgan Stanley decreased their target price on shares of Biogen from $157.00 to $152.00 and set an "equal weight" rating for the company in a research note on Wednesday, April 9th. HSBC lowered shares of Biogen from a "buy" rating to a "hold" rating and set a $118.00 target price for the company. in a research note on Monday. Hsbc Global Res lowered shares of Biogen from a "strong-buy" rating to a "hold" rating in a research note on Monday. Finally, Bank Of America (Bofa) decreased their target price on shares of Biogen from $178.00 to $163.00 and set a "neutral" rating for the company in a research note on Tuesday, February 11th. Twenty analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat, Biogen presently has an average rating of "Hold" and an average target price of $201.93.

Insider Activity

In other Biogen news, Director Stephen A. Sherwin sold 8,760 shares of the company's stock in a transaction on Friday, March 7th. The stock was sold at an average price of $150.02, for a total value of $1,314,175.20. Following the transaction, the director now owns 11,318 shares of the company's stock, valued at $1,697,926.36. This represents a 43.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 0.16% of the company's stock.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.